- Cypros is to expand its Phase II trial of CPC-111 in coronary artery bypass surgery patients, after additional data showed that the drug had cardioprotective properties, measured by an enzyme marker of cardiac cell death. The drug also had a statistically significant and positive effect on a number of key parameters of heart function, including demonstration of a positive inotropic effect, cardiac output, left ventricular stroke work index and cardiac index.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze